The ASCO Direct™ Highlights program reviews practice-changing data and other “hot topics” discussed at the premier clinical oncology conference in North America, including information about hematologic malignancies and thoracic, breast, gastrointestinal, genitourinary, gynecologic, and dermatologic tumors.

To minimize your time away from clinical practice, the ASCO Direct™ Highlights program will take place in a single weekend. Be sure to join us in June and July 2022 for this engaging and interactive session to learn about the most important findings in clinical oncology.

Choose the city or date that best works with your schedule to learn more!

Benefits of Attending:

• Learn from leading experts about important, potentially practice-changing data in oncology and hematology
• Gain insights into advances in tumor testing to optimize therapy
• Expand your knowledge of evolving therapeutic paradigms for patients with solid tumors or hematologic malignancies
• Enhance your ability to tailor treatment selection to individual patients with cancer

Benefits of Attending:

• Learn from leading experts about important, potentially practice-changing data in oncology and hematology
• Gain insights into advances in tumor testing to optimize therapy
• Expand your knowledge of evolving therapeutic paradigms for patients with solid tumors or hematologic malignancies
• Enhance your ability to tailor treatment selection to individual patients with cancer

Benefits of Attending:

• Learn from leading experts about important, potentially practice-changing data in oncology and hematology
• Gain insights into advances in tumor testing to optimize therapy
• Expand your knowledge of evolving therapeutic paradigms for patients with solid tumors or hematologic malignancies
• Enhance your ability to tailor treatment selection to individual patients with cancer

Benefits of Attending:

• Learn from leading experts about important, potentially practice-changing data in oncology and hematology
• Gain insights into advances in tumor testing to optimize therapy
• Expand your knowledge of evolving therapeutic paradigms for patients with solid tumors or hematologic malignancies
• Enhance your ability to tailor treatment selection to individual patients with cancer